ABSTRACT

Selegiline hydrochloride functions as an irreversible mono amino oxidase inhibitor and is typically prescribed to treat the symptoms of idiopathic Parkinson's disease. The microspheres were created for prolonged drug retention in the gastrointestinal tract, leading to improved oral bioavailability and superior absorption. Mucoadhessive microspheres were developed using the ionotropic gelation technique using different concentrations of sodium alginate, calcium chloride, carbopol 940p, and karaya gum with different levels of stirring speed. The optimization process was carried out using Design Export 13 software. Followed by investigating and comparing the pharmacokinetic profiles of selegiline hydrochloride pure drug and its microsphere optimized formulation in rat plasma by RP- HPLC using tetradeuteroselegiline as internal standard with a single oral administration of 0.129 mg. When compared with pharmacokinetic parameters of selegiline hydrochloride, the AUC0-t, AUC0–?, Tmax and t1/2 of selegiline hydrochloride microspheres were increased, while the Cmax was decreased. These results suggested that formulation modification of selegiline hydrochloride into microspheres enhanced bioavailability. Keywords: Selegiline hydrochloride, Parkinson’s disease, Mucoadhesive microspheres, Pharmacokinetics, HPLC
Publication date: 01/10/2023

https://ijbpas.com/pdf/2023/October/MS_IJBPAS_2023_7520.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2023/12.10.7520